Pfizer board member Dr. Scott Gottlieb said that the Omicron COVID-19 variant appears to confer some protection against an Omicron sub-variant known as BA.2 that was recently discovered in several countries.
“You should be protected. So the mutations in this new version are not in the receptor-binding domain on the spike protein,” Gottlieb told CBS News on Sunday morning. “That’s the portion of the spike protein that we develop our best antibodies against that neutralize the virus. Most of the mutations are in a separate part of the spike protein called the N-terminal domain.”
